Interestingly, it has been reported that the activity of the tetrameric form of PKM2 can be efficiently inhibited allosterically by the phosphorylated form of the high-mobility group box 1 (HMGB1) protein, leading to a rapid blockage of glucose-dependent aerobic respiration and cancer cell death making PKM2 an attractive therapeutic target [17,18]. The gene discussed is PKM; the disease is cancer.